Edition:
United Kingdom

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

65.88USD
6:20pm BST
Change (% chg)

$0.11 (+0.17%)
Prev Close
$65.77
Open
$65.30
Day's High
$66.94
Day's Low
$65.30
Volume
32,535
Avg. Vol
112,007
52-wk High
$66.94
52-wk Low
$36.55

Select another date:

Tue, Aug 28 2018

Emergent BioSolutions to buy Narcan maker Adapt Pharma

Emergent BioSolutions Inc said on Tuesday it would buy privately held Adapt Pharma, beefing up its portfolio with Narcan, the only FDA approved needle-free emergency opioid overdose treatment.

UPDATE 2-Emergent BioSolutions to buy Narcan maker Adapt Pharma

* Adapt partner Opiant soars in after-hours trading (Adds details and comment from conference call)

Emergent BioSolutions to buy Adapt Pharma for up to $735 mln

Aug 28 Emergent BioSolutions Inc said on Tuesday it would buy privately held Adapt Pharma for up to $735 million to acquire its drug Narcan, the only needle-free emergency treatment approved to treat opioid overdose.

BRIEF-Emergent BioSolutions Reports Q1 Adjusted Loss Per Share $0.03

* EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Emergent BioSolutions ‍Appoints Richard Lindahl As New Executive Vice President And Chief Financial Officer​

* EMERGENT BIOSOLUTIONS ANNOUNCES EXECUTIVE MANAGEMENT CHANGES THAT ENHANCE EXECUTION OF COMPANY’S GROWTH STRATEGY

BRIEF-Emergent Biosolutions To Implement Stock Repurchase Program

* EMERGENT BIOSOLUTIONS TO IMPLEMENT STOCK REPURCHASE PROGRAM FOR UP TO $50 MILLION OF ITS COMMON STOCK

Select another date: